Bevatas 300 mg Injection Supplier USA | Pharmaceutical Exporter from India

Bevatas 300 mg Injection: Targeted Anti-VEGF Therapy for Precision Oncology

Are you searching for a dependable Bevatas 300 mg Injection exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced biologics. We maintain a high-authority, cold-chain-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving anti-angiogenic treatments reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Bevatas 300 mg?

Bevatas 300 mg Injection is a recombinant humanized monoclonal antibody containing the active ingredient Bevacizumab. Manufactured by Intas Pharmaceuticals Ltd., Bevatas is a high-quality biosimilar designed to provide the same clinical efficacy and safety profile as the reference product Avastin.

For international B2B procurement, Bevatas 300 mg provides a clinically validated, cost-effective solution for treating various advanced malignancies. It is supplied as a 300 mg/12 ml concentrate for intravenous infusion.

Primary Therapeutic Indications

Bevatas 300 mg is used globally for:

1. Metastatic Colorectal Cancer (mCRC): Used in combination with fluoropyrimidine-based chemotherapy.

2. Non-Small Cell Lung Cancer (NSCLC): First-line treatment of unresectable, locally advanced, or metastatic non-squamous NSCLC.

3. Glioblastoma Multiforme: For adult patients with progressive disease following prior therapy.

4. Metastatic Renal Cell Carcinoma (mRCC): In combination with interferon-alpha.

5. Ovarian, Fallopian Tube, and Peritoneal Cancers: For advanced or recurrent stages of these conditions.

6. Cervical Cancer: In combination with paclitaxel and cisplatin or paclitaxel and topotecan.

Mechanism of Action: How Bevatas Works

Bevatas works through a precise mechanism known as angiogenesis inhibition:

• VEGF Binding: The antibody selectively binds to vascular endothelial growth factor (VEGF), a protein that stimulates the formation of new blood vessels.

• Starving the Tumor: By neutralizing VEGF, Bevatas prevents the growth of new blood vessels that tumors need to receive oxygen and nutrients.

• Tumor Regression: Existing tumor blood vessels may also shrink, slowing the progression of the cancer and enhancing the delivery of co-administered chemotherapy.

Administration and Clinical Safety

• Infusion Protocol: Bevatas must be administered as an intravenous infusion by a healthcare professional. It should never be given as an IV bolus or push.

• Storage Requirements: This biological product must be kept in a strict cold chain between 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.

• Key Safety Monitoring:

• Hypertension: Blood pressure should be monitored regularly during therapy.

• Wound Healing: It should not be used for 28 days before or after major surgery due to the risk of poor wound healing.

• Proteinuria: Regular urine testing for protein is recommended.

Why Source Bevatas from Ernest Oncology?

• Authentic Indian Exporter: Direct access to genuine Intas Pharmaceuticals inventory, providing 100% product authenticity and competitive wholesale pricing.

• Cold-Chain Authority: We utilize validated thermal shipping solutions to ensure Bevatas remains within the required temperature range during transit to the USA, UK, Australia, and South Africa.

• Regulatory Compliance: We provide all essential B2B documentation, including GMP compliance, batch-specific COAs, and necessary export permits.

• Bulk Supply Stability: We specialize in fulfilling large-scale orders for hospital groups, oncology clinics, and regional distributors.